New technologies in gynecologic cytology

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 45, Issue 9, 2000, Pages 701-719

  Bishop, J W ^a   Marshall, C J ^a   Bentz, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomedical technology; Cervical smears; Cervix neoplasms; Cytology

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; EVALUATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; PAPANICOLAOU TEST; PRIORITY JOURNAL; RELIABILITY; SAFETY; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX TUMOR; VIRUS DETECTION; WART VIRUS;

AUTOMATION; CARCINOMA; CYTOLOGY; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TECHNOLOGY, MEDICAL; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0033804459     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (186)

1. This diagnostic value of vaginal smears in carcinoma of the uterus
2. Cervical (Pap) smear: New directions
3. Cervix cancer control in Louisville, Kentucky
4. Cervix cancer death rates and mass cytologic screening
5. Evaluation of the effectiveness of cytologic screening for cervical cancer: I. Incidence and mortality trends in relation to screening
6. The role of cervical cytology in the declining morbidity and mortality of cervical cancer
7. Efficacy of screening for cervical cancer: A review
8. Cancer incidence and mortality trends among whites in the United States, 1947-84
9. Effect of a mass screening program on the risk of cervical cancer
10. The task force on cervical cancer screening programs
11. Recent results from the British Columbia screening program for cervical cancer
12. Cervical intraepithelial neoplasia in British Columbia: A comprehensive program for detection, diagnosis, and treatment
13. A cohort study of cervical cancer screening in British Columbia
14. Changes of morbidity and mortality from cancer of the cervix uteri in Puerto Rico
15. Cervical cancer screening in north-east Scotland
16. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes
17. Effect of organized screening on incidence and mortality of cervical cancer in Denmark
18. Invasive cancer of the cervix in British Columbia: A review of the demography and screening histories of 437 cases seen from 1985-1988
19. Screening for cancer of the uterine cervix in Greenland
20. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening, 1960-1984
21. Mass screening for cancer of the uterine cervix in Miyagi Prefecture, Japan: Effects and problems
22. Papanicolaou smear screening and cervical cancer: What can you expect?
23. Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implication for screening policies
24. Risk factors for cervical cancer by histology
25. Cancer prevention in primary care: Screening for cervical cancer
26. Cervical cancer detection in British Columbia: A progress report
27. A retrospective review of cervical cytology in women developing invasive squamous cell carcinoma
28. The cytologic history of 245 patients developing invasive cervical carcinoma
29. Invasive carcinoma of the cervix in young women
30. Invasive squamous cell carcinoma of the cervix after recent negative cytologic test results: A distinct subgroup?
31. Analysis of cervical smears obtained within three years of the diagnosis of invasive cervical cancer
32. The Papanicolaou smear histories of 237 patients with cervical cancer
33. The screening histories of women with invasive cervical cancer, Connecticut
34. Invasive cervical carcinoma in young women
35. False-negative cytology in invasive cancer of the cervix
36. False-negative results in cervical cytologic studies
37. Negative smears in women developing invasive cervical cancer
38. Advanced squamous cell carcinoma of the cervix with recent normal Papanicolaou tests
39. Evaluation of serial cervical cytology in the assessment of preinvasive cervical neoplasia
40. Cervical biopsy-cytology correlation: Data analysis and critique
41. Rescreening in gynecologic cytology: Rescreening of 3762 previous cases for current high-grade squamous intraepithelial lesions and carcinoma: A College of American Pathologists Q-Probes study of 312 institutions
42. Estimation of the screening error rate from the observed detection rates in repeated cervical cytology
43. Cervical intraepithelial neoplasia: III. An estimate of screening error rates and optimal screening interval
44. Meta-analysis of Pap test accuracy
45. Screening histories of incidence cases of cervical cancer and high grade SIL: A comparison
46. New technologies in cervical cytology screening: A word of caution
47. Cervical cancer after initial negative and atypical vaginal cytology
48. Results of prior cytologic screening in patients with a diagnosis of stage I carcinoma of the cervix
49. Cervical cancers diagnosed after negative results on cervical cytology: Perspective in the 1980s
50. Risk factors for rapid-onset cervical cancer
51. Our journey towards improved accuracy in cytology: The role of new technologies
52. Automated primary screening for gynecologic cytology: The time has not yet come
53. Who should decide how effective cervical cancer screening will be?
54. Automation of primary screening for cervical cancer: Sooner or later?
55. Lax Laboratories: The Pap test misses much cervical cancer through labs' errors
56. Physicians' carelessness with Pap tests is cited in procedure's high failure rate
57. The gynecologist's perspective of liability and quality issues with the Papanicolaou smear
58. Liability issues with the Papanicolaou smear: A defense lawyer's perspective
59. Liability issues with the Papanicolaou smear: The view of a hospital administrator at Newport Hospital, Newport, Rhode Island
60. Estimated cervical cancer disease state incidence and transition rates
61. Previous cytology in patients with invasive carcinoma of the cervix
62. The relationship of cervical cytology to the incidence of invasive cervical cancer and mortality in Alameda County, California, 1960 to 1974
63. Detection of uterine cancer: High and low risk groups
64. How preventable is invasive cervical cancer?: A community study of preventable factors
65. False-negative cytology rates in patients in whom invasive cervical cancer subsequently developed
66. Cervical smear histories of 500 women with invasive cervical cancer in Yorkshire
67. Carcinoma of cervix with recent normal Papanicolaou tests
68. Cervical cancer in women belonging to a cytologically screened population
69. Gynecologic specimen adequacy for flow system experiments
70. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor
71. Cell surplus on sampling devices after routine cervical cytologic smears: A study of residual cell populations
72. Study of cell loss in the conventional Papanicolaou smear
73. Numerical counts of epithelial cells collected, smeared and lost in the conventional Papanicolaou smear preparation
74. Diagnostic efficacy and validity of the ThinPrep method in cervical cytology
75. The false negative smear: II. The trapping effect of collecting instruments
76. Quality control in cervical cytology
77. False negatives in cervical cytology: Can they be avoided?
78. Influence of smear quality on the rate of detecting significant cervical cytologic abnormalities
79. The significance of endocervical cells in the diagnosis of cervical epithelial changes
80. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears
81. Indicators of effective cytological sampling of the uterine cervix
82. Components and results of a new preparation technique for automated analysis of cervical samples
83. Magnitude and character of errors produced by shape factors in Stoke's law estimates of particle radius
84. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening
85. Specimen adequacy of ThinPrep sample preparations in a direct-to-vial study
86. Validation of the ThinPrep Pap Test for cervical cancer diagnosis
87. Performance of a fluid-based, thin-layer Papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England
88. Evaluation of the Thin-Prep Pap test in clinical practice: A seven-month, 16,314-case experience in northern Vermont
89. ThinPrep Pap Test: Accuracy for glandular disease
90. Comparison of the CytoRich system with conventional cervical cytology: Preliminary data on 2,032 cases from a clinical trial site
91. The AutoCyte preparation system for gynecologic cytology
92. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears: Including initial biopsy results
93. CytoRich liquid-based cervical cytologic test: Screening results in a routine cytopathology service
94. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories
95. Biopsy-based comparison of liquid-based, thin-layer preparations to conventional Pap smears
96. Evaluation of the PAP-NET cytologic screening system for quality control of cervical smears
97. Computer-assisted rescreening of clinically important false negative cervical smears using the PAPNET Testing System
98. Preparation of clinical gynecologic specimens for automated analysis: An overview
99. A simple method of producing a monolayer of cervical cells for digital image processing
100. A preparation technique for exfoliated and aspirated cells allowing different staining procedures
101. CYBEST-CDMS: Automated cell dispersion and monolayer smearing device for CYBEST
102. Effect of the special properties of monolayer cell preparations for automated cervical cytology on visual evaluation and classification: With an estimation of the number of cells required to be screened
103. A new disaggregation device for cytology specimens
104. Techniques in the preparation of a monolayer of gynecologic cells for automated cytology: An overview
105. Automated screening of cervical cytology specimens
106. The AutoPap system for primary screening in cervical cytology: Comparing the results of a prospective, intended-use study with routine manual practice
107. Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: Results of a primary screening clinical trial
108. Performance of the AutoPap primary screening system at Jefferson University Hospital
109. Does use of the AutoPap assisted primary screener improve cytologic diagnosis?
110. NeoPath, Inc: NeoPath AutoPap 300 Automatic Pap Screener System
111. Enhancing the performance of the AutoPap 300 QC system with optimal staining and presentation of cervical smears
112. AutoPap system performance in screening for low prevalence and small cell abnormalities
113. A clinical trial of the AutoPap 300 QC system for quality control of cervicovaginal cytology in the clinical laboratory
114. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study
115. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies
116. Sensitivity of the AutoPap 300 QC System for cervical cytologic abnormalities: Biopsy data confirmation
117. Characteristics of false-negative smears tested in the normal screening situation
118. Determining the utility and effectiveness of the NeoPath AutoPap 300 QC System used routinely
119. Improved quality-control detection of false-negative Pap smears using the Autopap 300 QC system
120. Results of AutoPap system-assisted and manual cytologic screening: A comparison
121. Effectiveness of automated cervical cytology rescreening using the AutoPap 300 QC System
122. Computer-assisted cervical cancer screening using neural networks
123. PAPNET Testing System: Technical update
124. Significant reduction in the rate of false-negative cervical smears with neural network-based technology (PAPNET Testing System)
125. Neural network processing of cervical smears can lead to a decrease in diagnostic variability and an increase in screening efficacy: A study of 63 false-negative smears
126. Evaluation of PAPNET system for rescreening of negative cervical smears
127. Computer-assisted primary screening of cervical smears using the PAPNET method: Comparison with conventional screening and evaluation of the role of the cytologist
128. Efficacy of automated cervical cytology screening
129. Atypical squamous cells of undetermined significance: Current laboratory practices of participants in the College of American Pathologists Interlaboratory: Comparison Program in Cervicovaginal Cytology
130. PAPNET analysis of reportedly negative smears preceding the diagnosis of a high-grade squamous intraepithelial lesion or carcinoma
131. Evaluation of PAPNET-assisted cervical rescreening
132. Neural-network-assisted analysis and microscopic rescreening in presumed negative cervical cytologic smears: A comparison
133. A feasibility study of the AutoPap system location-guided screening
134. Sensitivity studies of AutoPap System Location-Guided Screening of cervical-vaginal cytologic smears
135. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective: International biological study on cervical cancer (IBSCC) Study Group
136. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
137. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women
138. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica
139. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
140. Utility of liquid-based cytology for cervical carcinoma screening: Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma
141. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
142. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions
143. Where's the high-grade cervical neoplasia?: The importance of minimally abnormal Papnicolaou diagnoses
144. Human papillomavirus (HPV) DNA assay as an adjunct to liquid-based Pap test in the diagnostic triage of women with an abnormal Pap smear
145. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing
146. Performance of liquid-based, thin-layer cervical cytology: Correlation with reference diagnoses and human papillomavirus testing
147. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears
148. Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study
149. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
150. Compatibility of the thinprep pap test and the LCX probe system chlamydia trachomatis assay
151. Rapid detection of HSV from cytologic specimens collected into ThinPrep fixative
152. The efficacy of an automated preparation device for cervical cytology
153. A new look at cervical cytology: ThinPrep multicenter trial results
154. Efficacy of ThinPrep preparation of cervical smears: A 1,000-case, investigator-sponsored study
155. ThinPrep Processor: Clinical trials demonstrate an increased detection rate of abnormal cervical cytologic specimens
156. Comparison of ThinPrep preparations with conventional cervicovaginal smears: Practical considerations
157. Cervical smears prepared by an automated device versus the conventional method: A comparative analysis
158. An Australian trial of ThinPrep: A new cytopreparatory technique
159. Would monolayers provide more representative samples and improved preparations for cervical screening? Overview and evaluation of systems available
160. Use of thin-layer preparations for gynecologic smears with emphasis on the cytomorphology of high-grade intraepithelial lesions and carcinomas
161. Conventional cervical cytologic smears vs. ThinPrep smears: A paired comparison study on cervical cytology
162. Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear
163. Improved accuracy for cervical cytology with the ThinPrep method and the endocervical brush-spatula collection procedure
164. Improving cervical cytology screening in a remote, high risk population
165. Comparison of fluid-based, thin-layer processing and conventional Papanicolaou methods for uterine cervical cytology
166. The coming revolution in cervical cytology: A pathologist's guide for the clinician
167. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system
168. The promise and risk of a new technology: The Lehigh Valley Hospital's experience with liquid-based cervical cytology
169. Use of the Thin Prep Pap Test in clinical practice
170. ThinPrep Pap Test: Performance and biopsy follow-up in a university hospital
171. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer
172. Preliminary evaluation of Cyto-Rich: An improved automated cytology preparation
173. The false negative rate in cervical cytology: Comparison of monolayers to conventional smears
174. Efficacy of monolayer preparations for cervical cytology: Emphasis on suboptimal specimens
175. Evaluation of the CytoRich slide preparation process
176. Application of the CytoRich monolayer preparation system for cervical cytology: A prelude to automated primary screening
177. Clinical trials of the CytoRich specimen-preparation device for cervical cytology: Preliminary results
178. Evaluation of the CytoRich technique for cervical smears
179. Comparison of conventional PAP smears with thin layer specimen (liquid-based PAP test) and correlation with cytopathological findings with HPV status using the Hybrid Capture System
180. AutoCyte prep system vs. conventional cervical cytology: Comparison based on 2,156 cases
181. Multicenter comparison of manual and automated screening of AutoCyte gynecologic preparations
182. AutoCyte Interactive Screening System: Experience at a university hospital cytology laboratory
183. Evaluation of the AutoCyte SCREEN system in a clinical cytopathology laboratory
184. AutoCyte SCREEN interactive automated primary cytology screening system: A preliminary evaluation